People · Operator
Named in public records as an officer, director or promoter · active 2015–2025 · Healthtech, Hospitals and Physicians, Other Technology, Other Health Care
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Equip Health, Inc. | — | Healthtech | Series C | $163.8M | $343.2M | 2019 |
| U S HealthVest, LLC | — | Hospitals and Physicians | Series C | $125.3M | $212.6M | 2015 |
| Protenus, Inc | — | Other Technology | Series B | $47.7M | $359.3M | 2018 |
| Artemis Health Inc. | — | Healthtech | Series B | $46.4M | $566.7M | 2017 |
| PatientPing, Inc. | — | Other Health Care | Series B | $41.4M | $701.2M | 2015 |
| nOCD, INC. | — | Other Technology | Series B | $36.7M | $680.2M | 2021 |
| Better Life Partners Inc. | — | Other Health Care | Series B | $33.9M | $231.8M | 2020 |
| Auxilus Inc. | — | Other Technology | Series A | $10.0M | $64.9M | 2024 |
| Well Beam, Inc. | — | Other Health Care | Series A | $7.7M | $97.8M | 2021 |
Jon Lim at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Jon Lim on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Stephen Smith | 1 | 17 |
| Andrew Adams | 1 | 13 |
| Liam Donohue | 1 | 12 |
| Glen Tullman | 1 | 12 |
| Brian Chee | 1 | 10 |
| Dalton Wright | 1 | 10 |
| David Tamburri | 1 | 10 |
| Jonathan Lim | 1 | 9 |
| Jared Kesselheim | 1 | 7 |
| Stephen Kraus | 1 | 7 |
| Holly Maloney | 1 | 7 |
| Jesse Jacobs | 1 | 6 |
| Ambar Bhattacharyya | 1 | 6 |
| Edward Michael | 1 | 6 |
| Grant Gordon | 1 | 5 |
| Krishna Yeshwant | 1 | 5 |
| Robert Lord | 1 | 5 |
| Ross Fubini | 1 | 5 |
| Steven Kelly | 1 | 4 |
| James Burgum | 1 | 4 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.